Composition for appetite control and management and weight regulation

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to food and chemical-pharmaceutical industry, namely to creation of a concentrated oil/water emulsion of replacement fat of zero caloric content intended for both appetite control and management, and weight regulation. A composition for appetite control and management, and weight regulation, represents the concentrated emulsion containing replacement fat with zero caloric content selected from a group of saccharose polyesters consisting generally of mixed saccharose octa-, hepta- and hexaesters, triglycerides of caprylic/capric fatty acids, edible Vaseline oil, an emulsifying stabiliser selected from the group: gum arabic, saponin, modified starch, a flavour additive, a preservative, vitamin A, beta carotene and water taken in certain proportions.

EFFECT: received composition shows high functional activity of the developed concentrated emulsions in the prescribed sparing mode of therapy "ГЛ".

3 cl, 1 tbl


The invention relates to the food and pharmaceutical industry, namely: the creation of a concentrated emulsion of the type oil/water-based Jerusalemites with zero calorie designed as to control appetite and weight regulation, and as a raw material for biologically active additives to food and/or pharmaceutical preparations, dietetic and functional foods to reduce calorie fat-containing products.

The emulsion reduces the absorption of bile acids in the small intestine and has a blocking effect against the enterohepatic circulation of bile acids.

The emulsion can be attributed to pharmaceutical preparations which can be used in medicine for the normalization of lipid metabolism and the physiological state of the organism as a whole in the prevention and conservative treatment of various diseases, which are based on such a pathogenetic factor as dyslipoproteinemia (DLP) and, in particular, hyperlipidemia (CH) (Thompson G.R. Handbook of heperlipidemia. London, 1991), as well as to restore the natural mechanism of cholesterol homeostasis and normalize bile-acid metabolism.

Preventive and therapeutic effects on the body emulsions with functional properties is to not upset the usual mode of life, "gently" to monitor and control appetite, regulate weight and gradually bring to normal lipid spectrum of blood plasma (cholesterol, triglyceride, low density lipoprotein and others) and thereby prevent the development of pathogenic factors such as DLP (RF Patent N 2008821, AV 17/00, 14.10.91, Ross R., Harker L. Hypelipidemia and atherosclerosis, Science, 1976. Vol.193. pp.1094-1100).

Known application in pharmacological therapy DLP and, in particular, hyperlipidemia (HL) drugs that reduce the absorption of bile acids in the small intestine (cholestyramine, colestipol, polifan, chitosan, etc.) (Lipid Research Clinics Program // The Lipid Rescarch Clinics Coronary Primary Prevention Trial results. 1. Reduction in incidence of coronary heart disease // JAMA. - 1984. - Vol.251. - P.351-364). However, there is a risk of development of various complications and there are contraindications, especially with long-term use of the drugs of this group.

Now proven to be the most effective in the prevention and treatment of DLP is emulsion-based form vaseline (white) oil.

Pasta "Visant With" drug "Ficant. Leaflet company LTD. Penta Honey", RF patents №2008821; 2054931; 2128991, RF Patent №2008821, AV 17/00, 14.10.91, RF Patent №2054931, A61K 9/107, 01.06.94) is a vaseline-Pechino-agar emulsion and is used in the treatment and prevention DLP together with choleretic drug is mi and, if necessary, with drugs, enhance intestinal peristalsis (Yablokov Mrs x, Petukhov V.A., Kuznetsov MR, Krayushkin AV Dyslipoproteinemia and atherosclerosis. New perspectives for diagnosis and treatment. Ed. by Acad. The RAMS Savelyeva B.C. - M., 1996, pp.69-76).

Vaseline edible oil, encapsulated inside the pectin-agar shell dissolves and absorbs bile acids, and then transports them into the large intestine. Bile acids along with the oil removed from the colon with feces. Insufficient return of bile acids to the liver (as opposed to a healthy person) requires synthesis of a new portion of bile. This requires cholesterol, which is the basis of bile acids. He comes from blood plasma and other depot is converted into bile acids and leaves the liver together with gall. Thus, restores the natural mechanism of circulation of bile acids and fecal excretion of cholesterol.

Molecules of polysaccharides, pectin and agar, are part of the drug is not absorbed in the small intestine, as resistant to the action of various enzymes. An important feature of these polysaccharides is the ability to bind heavy metals and toxins that can be attributed to the drug to the active chelators.

The main advantage of the paste Ficant-in comparison with the known pharmacological trail is t to rebuild the natural mechanism of cholesterol homeostasis.

Paste Ficant-take 1 once a week dose of 200 g of paste per day for 4-12 months. This corresponds to 75-80 g of paraffin oil with a single admission.

The product contains the following components in wt.%: vaseline oil - 38.5, pectin - 6,0, agar - 0,5, jelly with carrot - 14,5, distilled water - the rest.

The main disadvantage paste Ficant-is the presence in the composition of the synthetic vaseline edible oil (a mixture of saturated hydrocarbons - oil fraction), which is hard to call a food product for everyday use. In addition, it is known that prolonged use of mineral oil, even in small doses, can disrupt the digestive process.

Recommended therapeutic daily dose consumption of mineral oil as a laxative is 1-3 tablespoons per day (40-50 ml), and consumed daily dose of mineral oil in the pasta Ficant-With almost 1.5 times higher than the adequate therapeutic dose, as noted above.

Therefore, such a synthetic product may not be recommended for use as a nutritional diet product to control appetite control and weight management in "soft" prevention of obesity.

An obvious disadvantage paste Ficant-is also overestimated the amount of dietary fiber recommended in the daily dose, which is - 13 g, which exceeds the maximum adequate level of daily consumption of Pectin and Agar almost 2.5 times (Rational nutrition. Recommended levels of consumption of food and biologically active substances. Methodology N MP dated 2 July 2004).

Limited shelf life under normal conditions is only 2 months, is also the added disadvantage paste Ficant-C.

The closest solution to the proposed invention is a beverage in the form of a concentrated emulsion based liquid Jerusalemites grade Olestra-Olean (dietary fat) with zero calories, which by its chemical nature is the product of the synthesis of sucrose and vegetable oils and is a liquid not absorbed in the body product in the form of a mixture of polyesters of sucrose (Technical information OLEAN company The Procter & Gamble Co.).

The emulsion is used as a substitute for dietary fat for fat and hypercholesterinemia patients.

In the concentrated beverage composition in the form of monocroptophos emulsion-based Jerusalemites includes: representing a liquid the consistency of the sucrose polyester (a mixture of hexalate [77138-73-9], septolete [77138-74-0] and octaoleate [34816-23-4] sucrose) in the amount of 43.5 wt.%, solid palm oil - 10.9 wt.%, sucrose - 10.5 wt.%, milk protein - 3.8 wt.%, poly is literally ether (average 3 glycerolic unit, With14-C18fatty acid esters) and 1.8 wt.%, propylene glycol ether (85 wt.%, monopalmitate [29013-28-3]) - 1.8 wt.%, Xanthan of gum to 1.0 wt.%, powder vanilla - 0.3 wt.%, flavor - 0.1 wt.%, potassium sorbate - 0.06 wt.%, citric acid is 0.04 wt.%, water - to 26.2 wt.% (European patent EP 0069412 (A1), 1983-01-12).

The disadvantages of this emulsion are: the presence in the diet product solid palm oil in concentrations of more than 10 wt.%, which is an additional source of excess calories along with carbohydrates - sucrose (10.5 wt.%) and milk protein (3.8 wt.%), as well as the presence polyglycerols and propylene glycol ethers - a total of 3.8 wt.%, making extra calories, which reduces the effectiveness of this emulsion, as a dietary product.

It is known that in the brand Olean-Olestra not only has liquid girasolereale with zero calories, as presented in the discussion part, but substitutes (DairyLean P, J, E), which contain a fraction of solid fat, which does not allow to obtain on the basis of their stable direct emulsion type oil/water.

The disadvantages also include the inability to use the entire line of substitutes with zero calories, including those in which high fractions of refractory solid fats increases the prospects of this brand as di the political product.

In U.S. patent No. 5516544, 4368213, 4705691, 6447824 number of traditional substitutes is preferably at least about 20.0 wt.% and most preferably at least about 75,0 wt.% by weight of the total oil in the emulsion.

The purpose of this invention is to provide means in the form of a concentrated emulsion-based Jerusalemites with zero calories, suitable for use as a raw material for biologically active food additives for use in the food industry and the quality of the product Wellness diet and clinical nutrition.

The technical result of the invention is the improvement of consumer characteristics, such as taste characteristics, in particular the aftertaste, which is expressed in disguise of osalennosti at high concentrations of synthetic Jerusalemites, coagulation and sedimentation stability during prolonged storage in the form of a concentrated emulsion with preservation of the sphericity of the particles Jerusalemites. As well as using the total number of substitutes, including products with high fractions of refractory solid fat, not giving the possibility of obtaining a stable emulsion with spherical particles.

To do this, as emulsifiers-stabilisers used hydrocolloids with value and emulsifying properties, that allows not only to increase the shelf life of the product under normal conditions, but additionally to improve therapeutic efficacy of a concentrated emulsion due to the surfactant properties of hydrocolloids, as well as to raise the concentration of Jerusalemites in the emulsion and to enter as fat phase full range of substitutes with zero calories.

The problem is solved as follows.

The proposed biologically active composition to control appetite and weight regulation, represents a concentrated emulsion containing girasolereale with zero calorie selected from the group of polyesters of sucrose, consisting mainly of a mixture of OCTA-, hepta - and Hexaemeron sucrose, triglycerides of Caprylic/capric fatty acid, liquid paraffin food, emulsifier-stabilizer selected from the group of: gum Arabic, saponins, modified starch, flavoring additive, preservative, vitamin a, beta-carotene and water in the following components in wt.%:

girasolereale with zero calories20,0-60,0
triglycerides of Caprylic/capric fatty acids0.01 to about 30.0
vaseline oil for food0.01 to about 30.0
emulsifier-stabilizerof 0.5 to 20.0
flavoring natural Supplement0,1-2,0
vitamin a0,001-0,01
beta carotene0,001-0,01
waterthe rest of it.

The composition of Jerusalemites with zero calorie selected from the group of polyesters of sucrose, consisting mainly of a mixture of OCTA-, hepta - and Hexaemeron sucrose (product Information Olean, p.20 and Specification of products Olean, The Procter & Gamble With. Food ingredients, USA).

In this composition flavoring additive is selected from the group of natural concentrates produced by fermentation of various milk fat with the release of fatty acids (U.S. Patent No. 3653921, Technical information and specifications company ButterBuds. Food ingredients, USA).

The composition of a preservative selected from the group of potassium sorbate, sodium benzoate.

All food hydrocolloids new generation approved for use by the Committee of experts of the FAO/who as PI is of evich additives and are effective emulsifiers-stabilisers, enhanced coagulation and sedimentation stability of the concentrated emulsion system when the increase in the content of oil phase (Jerusalemites) up to 60 wt.%, as well as stability when diluted in a wide range of pH (from pH 3.0 to 8.0).

Concentrated form of emulsion (20-60 wt.%) allows you to reduce the dose a single dose of diet product, to improve its ability to sorbirovaniya bile acids as the active and inactive forms in the small intestine, and to stimulate the contraction of the walls of the large intestine, increasing therapeutic effectiveness of diet.

Introduction to the composition of preservatives in the range of 0.05-0.5 wt.%, (sorbic acid and its salts, sodium benzoate and other substances permitted for use by the Committee of experts of the FAO/who as food additives that prevent microbial and oxidative spoilage) provides increased shelf life of the drug up to 24 months at room temperature.

Flavoring concentrated natural supplements simultaneously solve two important tasks. Firstly, they improve the organoleptic properties of the composition, giving specific milky creamy taste of the product, and reduce unpleasant aftertaste, which is expressed in disguise of osalennosti when high is their concentrations Jerusalemites. Secondly, as on the chemical nature of fatty acids, they perform in the emulsion role of an additional emulsifier-stabilizer.

Introduction the formulation of vitamin a (retinol and/or in the form of provitamin beta-carotene) recommended by The Procter & Gamble With. for the correction of loss by the body of these vitamins during extended use in the dietary of these substitutes.

We offer a concentrated emulsion is prepared as follows.

Pre-prepared aqueous solution of the emulsifier-stabilizer preservative with water-soluble flavoring additive at a temperature not lower than 70-80°C. Then the resulting solution of the emulsifier slowly with vigorous ultrapremium (install the rotor/stator) at speeds from 3000 to 15000 rpm make a pre-prepared molten liquid oil phase containing oil OLEAN-OLESTRA, MCT oil, vaseline, cooking oil, vitamin a and oil soluble flavoring additive (70-80°C), was dispersed to obtain a homogeneous mass and after cooling the resulting homogeneous emulsion mass to a temperature of 30-40°C is added a pre-prepared solution beta-carotene and then re-dispersed in ultrameal for 5-10 minutes at a speed of not less than 3000-5000 rpm and/or optionally, homogeny irout at a pressure of 200 to 250 MPa 2-3 cycles on the high-pressure homogenizer.

The table below shows examples of various formulations of concentrated emulsions based Jerusalemites with zero calories.

Presented in table concentrated emulsion-based Jerusalemites with zero calories and emulsion-based composite compositions of substitutes oil (MCT oil and vaseline edible oil) have been used in the prevention AGP.

At long, 4-9 months, "soft" therapy CH preventive primarily for the management and control of appetite and weight management used the concentrated emulsion (20-55 wt.% Jerusalemites with zero calories) at a daily intake of no more than 30-50 g of the emulsion with an interval of 1-2 days.

Obtained preliminary data on the effect of the emulsion on the management and control appetite and weight control, as well as data on blood levels of cholesterol (LDL), triglycerides (TG), lipoprotein and high low-density (HDL and LDL) for a group of volunteers from 25 persons for a specified period up to 9 months show high functional activity developed concentrated emulsion at the desired operational mode of therapy CH.

It is noted that regardless of the time of admission (before or after a meal) and the concentration of Jerusalemites in emulsion (20-60 wt.%), after receiving a single dose of 20 g tako the emulsion is committed to sustainable long-term (up to 2-4 hours) loss of appetite. After 3-4 weeks of regular use emulsion duration of the lack of appetite is increased to 5-7 hours.

Monthly weight loss averaged 1.0 to 1.5 kg

The content of cholesterol in blood plasma decreased by 10-30%, triglyceride by 15-35%, LDL by 15-40%, and HDL increased by 5-15%.

Using the composition on the basis of a concentrated emulsion of Jerusalemites with zero calories as raw materials for the food industry for making it in the diet and dairy foods to reduce calorie primarily fat-containing products, including milk, sour cream, cream, mayonnaise, dairy products (yogurt, kefir), pastries, etc. it is necessary to consider the contents of Jerusalemites in concentrated emulsions and technological features of manufacture of these products.

The recommended level of introduction of the composition in the form of a concentrated emulsion in diet dairy products is 5 to 30 wt.%, that allows to reduce significantly the caloric content of these products and at the same time to solve the problem of control appetite and weight regulation in everyday products.

1. Biologically active composition to control what petiton and weight management characterized by the fact that it represents a concentrated emulsion containing girasolereale with zero calorie selected from the group of polyesters of sucrose, consisting mainly of a mixture of OCTA-, hepta - and Hexaemeron sucrose, triglycerides of Caprylic/capric fatty acid, liquid paraffin food, emulsifier-stabilizer selected from the group of: gum Arabic, saponins, modified starch, flavoring additive, preservative, vitamin a, beta-carotene and water in the following content, wt%:

girasolereale with zero calories20,0-60,0
triglycerides of Caprylic/capric fatty acids0.01 to about 30.0
vaseline oil for food0.01 to about 30.0
emulsifier-stabilizerof 0.5 to 20.0
flavoring natural Supplement0,1-2,0
vitamin a0,001-0,01
beta carotene0,001-0,01

2. The composition according to claim 1, where natural flavoring additive is selected from natural concentrates produced by fermentation of various milk fat with the release of fatty acids.

3. The composition according to claim 1, where the preservative is selected from the group of: potassium sorbate, sodium benzoate.


Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to production of a drug preparation in the form of a fluid mixture of glass particles containing drugs and a fluid medium. A creamy or pasty consistence of the fluid mixture is formed by adding a small amount of the liquid to particles. The mixture does not contain an excess amount of the liquid, therefore the mixture is not exfoliated.

EFFECT: provided wide range of liquid carriers accessible in preparations of this type.

3 cl, 3 dwg

FIELD: nanotechnologies.

SUBSTANCE: invention relates to method of water-in-oil and oil-in-water nanoemulsions preparation, where a disperse phase is distributed in a disperse phase in the form of drops with diameter from 1 to 500 nm, which includes the following stages: 1) preparation of homogeneous water/oil mixture (1) characterised by surface tension of less than 1 mN/m, including water in amount from 30 to 70 wt %, at least two surfactants with different HLB selected from nonionic, anionic, polymer surfactants, besides, the specified surfactants are present in an amount to make the mixture homogeneous; 2) dissolution of the mixture (1) in the disperse phase, made of oil or water with addition of a surfactant selected from nonionic, anionic, polymer surfactants, besides, amount of the disperse phase and the surfactant is such that a nanoemulsion is produced with HLB differing from the HLB of the mixture (1). Invention also relates to water-in-oil nanoemulsions produced by this method with value of HLB from 6 to 14 and containing water in the amount from 1 to 30%, total amount of surfactants is from 0.1 to 20%, besides, the remaining amount (up to 100%) makes oil or oil in water, having the value of HLB that is more than 10, and containing oil in amount from 1 to 30%, total amount of surfactants is from 0.1 to 20%, and the remaining amount (up 100%) is water. The invention also relates to application of these nanoemulsions as carriers of additives in food, oil, cosmetic, pharmaceutical industries and in fuel sector.

EFFECT: method ensures production of water-in-oil or oil-in-water nanoemulsions with high stability, a more simple and a wider area of application.

33 cl, 26 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a chrysophanol conjugate or its derivative, characterised by general formula (I), in which R1-R8 is a group selected from -H, -OH, -OCH3, -CH3, provided that not less than two groups from R1-R8 denote -H or provided that one or two of groups R2, R3, R6 and R7 are a -COOH group, M is a nitrogen organic base selected from a group comprising chitosamin, glucosamin, or a basic amino acid selected from a group comprising arginine, lysine, carnitine, and group M is bonded to the chrysophanol part in the conjugate.

EFFECT: invention relates to use of the conjugate as a medicinal agent for preventing or treating diabetic nephropathy, osteoarthritis, rheumatic or rheumatoid arthritis, intestinal adhesion, intestinal peristalsis restoration, and a medicinal agent based on the conjugate.

8 cl, 4 dwg, 57 ex, 18 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and deals with elaboration of method of obtaining blood-substituting composition on two high pressure desintegrators from the mixture of two perfluorocarbons, quickly excreted (C8-C10) and(or) slowly excreted (C11-C12), is emulsified with proxalon-268 from 0.2% to 20% with molecular weight 6-12 thousand Da, with further addition of acceptable electrolyte solution, with formation of fine dispersion emulsion with the average particle size 30-120 nm. Method is realised by homogenisation of obtained mixture on two high pressure homogenisers with two or four extrusion devices of homogenisers.

EFFECT: method makes it possible to obtain highly stable perfluorocarbonic emulsions, which possess lower reactogenicity.

12 cl, 6 ex, 1 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical and cosmetic industry, and concerns development of a new safe and nontoxic composition of perfluorocarbon emulsion with colloidal silver, to ensure new, intensified properties for effective medicobiological and cosmetic application. Substance of the invention consists in development of a composition of perfluorodcalin (PFD) or perfluorotributylamine (PFTBA), or perfluoroctylbromide (PFOB), or perfluoromethylcyclohexyl-piperidine (PFMCP), proxanol, sodium chloride and colloidal silver; or mixed PFD/PFMCP, or PFD/PFTBA, or PFOB/PFTBA, or PFOB/PFMCP, proxanol, sodium chloride and colloidal silver; or mixed PFOB/PFD/PFMCP or PFOB/PFD/PFTBA, proxanol, sodium chloride and colloidal silver; or mixed PFOB/PFD/PFMCP/PFTBA, proxanol, sodium chloride and colloidal silver. The concentration of colloidal silver in the perfluorocarbon composition makes 0.00006-0.6 wt %.

EFFECT: composition exhibits high efficacy and stability.

17 cl, 12 ex

FIELD: medicine.

SUBSTANCE: in claimed methods pharmaceutical substance, which contains active ingredients, is introduced in form of microemulsion. Microemulsion is introduced by means of application system, which makes it possible to disperse microemulsion by gaseous medium, containing at least 25 vol. %, preferably, at least, 50 vol. % of oxygen.

EFFECT: efficient local delivery into skin of medications, including little and poorly-soluble, due to synergic action of active element of medication and oxygen, supplied under pressure and considerably increasing microcirculation.

20 cl, 3 tbl, 4 dwg, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of medicine, namely, to chemical-pharmaceutical industry, in particular, to block-copolymer pharmaceutical compositions, containing 3,3'-diindolylmethane (DIM). Invention also relates to methods for treatment of various diseases with the help of specified compositions.

EFFECT: compositions improve absorption of active compound into blood flow in case of its peroral delivery.

6 cl, 4 dwg, 2 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention relates to spontaneously dispersed pharmaceutical compositions including substance P antagonist, 5-aryl-4(K)-arylcarbonylaminopent-2-enic acid, and carrier medium, including from 5 to approximately 85 wt % of lipophilic component, namely monoglycerides and diglycerides of C8-C10 fatty acids or purified with re-etherificated glycerol corn oil, and from 5 to approximately 90 wt % of surface active substance, namely l ether of polyethelene glycol and hydrogenised castor oil. Compositions by invention are stable and possess improved bioavailability.

EFFECT: invention also relates to methods of obtaining said compositions and methods of treating diseases which are cured with substance P antagonist, for instance respiratory diseases, intestinal disorders, enuresis and cough.

13 cl, 1 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to food, pharmaceutical and cosmetic industry, in particular deals with oil-in-water emulsion, containing disperse oil drops which have nano-size self-arranging structured internal contents, including: (i) oil, (ii) lipophilic additive (LPA), (iii) hydrophilic domains in form of drops or small canals, containing water or non-water polar liquid, and continuous water phase, which contains emulsion stabilisers or emulsifiers, in which oil drops with diametre from 5 nm to 900 mcm possess nano-size self-arranging structuring with formation of hydrophilic domains with diametre from 0.5 to 200 nm due to presence of lipophilic additive.

EFFECT: invention provides structures able to solubilise not only lipophilic but at the same time hydrophilic and/or amphiphilic, or hydrotropic, or crystalline components.

8 cl, 16 ex, 18 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared invention refers to chemical-pharmaceutical industry, and concerns an emulsion of perfluororganic compounds (PFOC) for medicine and biology, containing mixed perfluorocarbons (PFC) with a main ingredient being perfluorodecahydronaphthalene (PFD) and mixed perfluorochemical tertiary amines (PFTA) with a main ingredient being perfluoro-N-(4-methylcyclohexyl)-piperidine (PFMCP), having smaller excretion rates than PFD, a stabilising agent and a physiologically acceptable water-salt solution with energy metabolism substrata, differing that all the ingredients of PFOS have critical hexane solution temperatures (TcrH), differing no more than by 2-4°C, and the stabilising agent represents mixed block copolymers from the group of block copolymers polyoxyethylene-polyoxypropylene with an average weight content of polyoxypropylene 20%. The invention also concerns a method for making said emulsion, and a method of treating with applying the declared emulsion.

EFFECT: prepared emulsions show high stability and are non-toxic.

21 cl, 5 tbl, 17 ex, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and pharmacology and represents oncologic sensibiliser, which contains compound, selected from glucosamine, glucosamine derivative, represented by formula 2.

EFFECT: reduction of chemoresistance of cancer cells.

4 cl, 4 ex, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgical dentistry and maxillofacial surgery, and aims at treating alveolitis. After local anaesthesia, pharmacological treatment and curettage, an alveolar socket is 2/3 filled with a mixture of the osteoplastic material 'Bialgin' of granule size 1 mm and 30 % lincomycin hydrochloride gel in ratio 1:2, covered with the biologically resorbed membrane 'Collost' and a trapezoid mucoperiosteal flap cut out of a transitory fold of a cheek with its base turned to a buccal wall of the socket so that edges of the flap overlap membrane by 2 mm.

EFFECT: method allows to prevent development of inflammatory complications, atrophy of an alveolar process, to reduce convalescence of patients.

4 ex

FIELD: medicine.

SUBSTANCE: invention relates to pharmacology and medicine. Pharmaceutical composition for reduction of excess sugar levels in blood of type 2 diabetes mellitus patients, containing at least one cyanogenic glycoside from bitter almond kernels as active ingredient.

EFFECT: invention provides for use of natural source in composition for reduction of sugar in blood.

4 cl, 7 ex, 2 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: given invention refers to medicine and concerns a combination for treating an oncological disease, containing as an active ingredient, at least one immunostimulating drug of general formula and one or more chemotherapeutic agents chosen from the group consisting of alkylating agents including carboplatin, cisplatin and oxaliplatin, cytostatic agents chosen from cyclophosphamide and its derivatives, and antimetabolites chosen from fluorouracila and its derivatives, and to a method of treating oncological conditions.

EFFECT: invention provides higher clinical effectiveness.

18 cl, 8 dwg, 5 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: for complex treatment of perinatal pointed condylomatosis in outpatient and polyclinic conditions during 10 days peroral introduction of iodantipyrin in dose 200 mg 3 times a day is carried out. Three days after beginning of iodantipyrin introduction bipolar diathermia of perinatal condylomes is performed to healthy tissues, electrodes being applied step-by-step in zigzag order on condyloma circumference. After that in region of operation applied are bandages with solution, containing 200 mg of iodantipyrin and 20 mg of licopid in 200 ml of physiologic solution, or with celandine sap. Bandages are alternated every other day during 14 days.

EFFECT: reduction of disease recurrence, reduces terms of post-operation wound healing and temporary disability.

1 ex, 1 dwg

Sweetening agent // 2376886

FIELD: food industry.

SUBSTANCE: invention relates to chemical and pharmaceutical industry and concerns production of sweeteners containing stevioside. Stevioside is mixed with lactose, sodium carboxy-methylcellulose and leucine and produced in form of tabs by direct pressing on rotary tablet press.

EFFECT: obtained tabs of food sweetener have improved stability while storaging.

4 ex, 7 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medical products and covers applications of O- and S-glycosides 5-hydroxy-1,4-naphthoquinone (judlone) derivatives of formula 1 as an agent that stimulates human leukaemia cell apoptosis. Disclosed compounds selectively stimulate human leukemia cell apoptosis as comparrf with a prototype juglone without affecting normal cells of human immune system (neutrophils).

EFFECT: invention allows extending range of products selectively stimulating leukaemia cell apoptosis.

4 cl, 13 dwg, 5 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: invention relates to the new hem-difluoridated compound of the formula: where R1 represents a group, containing alkyl chain or amino group; R2 represents hydrogen atom, either free or protected functional group of alcohol; R3 represents a group CH2OH, CH2-OGP, where GP respresents protecting group such as alkyl, benzyl (Vp), trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS), acetate (Ac); Y, Y', Y" represent independent groups OR, where R represents H, benzyl, Ac, TMS, TBDMS, TBDPS that are used for producing antitumor, antiviral, hypoglycemic and anti-flammatory medicine and compounds for immunology and cosmetology, or glyco peptide analogs of antifreeze molecules. The invention refers particularly also to the new hem-difluoridated compound of the general formula: and to the method of producing new hem-difluoridated compound of the formula: .

EFFECT: compounds possess increased effectiveness.

7 cl, 8 ex, 24 dwg

FIELD: medicine.

SUBSTANCE: for treating patients suffering from chronic brucellosis, therapeutic complex includes an antibiotic, as well as Licopid and Tamerite. The preparations are introduced in therapeutic doses.

EFFECT: choice of specific preparations from the group of immunomodulators and antioxidants for specific infections provides long remission and prevention of unfavourable outcome of brucellosis.

3 ex, 3 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to gastroenterology and cardiology and concerns method of objectifying indications for choosing treatment of patients with ulcer disease (UD) in combination with artery hypertension (AH). For this purpose in accordance with WHO/ISAH classification of 1999, degree of AH and risk of development of cardio-vascular complications (RDCVC) is determined for patients. Patients with UD in combination with AH of I degree and RDCVC of 1-4 degree, as well as patients with UD with AH of II degree and RDCVC of 2 degree undergo traditional anti-ulcer and conventional hypertension therapy. Patients with UD and AH of II degree and RDCVC of 3-4 degree and patients with UD and AH of III degree and RDCVC of 4 degree are examined for presence of immune disorders, intestine disbacteriosis, depressive disorders, sympaticotonia, metabolic syndrome. If said disorders are found immunomodulators, antidepressants, vegetotropic medications are administered and metabolic syndrome therapy is performed, as hypotensive medications ACE inhibitors are introduced. Patients with UD with AH of III degree and RDCVC of 4 degree are administered combined therapy with ACE inhibitors and pulse slowing calcium antagonists, excluding preparations with make QT interval longer.

EFFECT: method ensures individualised treatment of said category of patients taking into account unfavourable development of ulcerous process depending on expression of systemic microcirculation disorders, determined by AH and RDCVC degree, which allows to influence different links of pathologic process fully and prevent development of complications.

8 tbl, 2 ex

FIELD: medicine, therapeutic stomatology.

SUBSTANCE: method involves administration of the medicinal composition into parodontal pockets that is prepared ex tempore and comprising 2 parts of porous hydroxyapatite ceramic with granules size 0.3-0.5 mm, 1 part of zinc oxide powder with addition of 30% solution of lincomycin. Also, method involves coating with fluorolacquer for 12-24 h with treatment course by 6-8 procedures for every day. Method provides effective treatment, prolongation of stable clinical remission being without surgery operation. Invention can be used in treatment of parodontitis of middle severity degree.

EFFECT: improved method of treatment.

7 dwg, 3 ex